No correlation between TIMP2 -418 G>C polymorphism and increased risk of cancer: evidence from a meta-analysis.
Tissue inhibitor of metalloproteinase (TIMP2) is involved in the regulation of matrix metalloproteinase 2 (MMP2) and shown to implicate in cancer development and progression. The results from the published studies based on the association between TIMP2 -418 G>C polymorphism and cancer risk are in...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4138026?pdf=render |
id |
doaj-d9921c70d88146459881dbe72b6549c5 |
---|---|
record_format |
Article |
spelling |
doaj-d9921c70d88146459881dbe72b6549c52020-11-24T21:26:33ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0198e8818410.1371/journal.pone.0088184No correlation between TIMP2 -418 G>C polymorphism and increased risk of cancer: evidence from a meta-analysis.Raju K MandalNaseem AkhterShafiul HaqueAditya K PandaRama D MittalMohammed A A AlqumberTissue inhibitor of metalloproteinase (TIMP2) is involved in the regulation of matrix metalloproteinase 2 (MMP2) and shown to implicate in cancer development and progression. The results from the published studies based on the association between TIMP2 -418 G>C polymorphism and cancer risk are inconsistent. In this meta-analysis, we aimed to evaluate the potential association between TIMP2 -418 G>C polymorphism and cancer risk.We searched PubMed (Medline) and EMBASE web databases to cover all studies based on relationship of TIMP2 -418 G>C polymorphism and risk of cancer until October 2013. The meta-analysis was performed for selected case-control studies and pooled odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated for all genetic models.A total of 2225 cancer cases and 2532 controls were included from ten eligible case-control studies. Results from overall pooled analysis suggested no evidence of significant risk between TIMP2 -418 G>C polymorphism and cancer risk in any of the genetic models, such as, allele (C vs. G: OR = 1.293, 95% CI = 0.882 to 1.894, p = 0.188), homozygous (CC vs. GG: OR = 0.940, 95% CI = 0.434 to 2.039, p = 0.876), heterozygous (GC vs. GG: OR = 1.397, 95% CI = 0.888 to 2.198, p = 0.148), dominant (CC+GC vs. GG: OR = 1.387, 95% CI = 0.880 to 2.187, p = 0.159) and recessive (CC vs. GG+GC: OR = 0.901, 95% CI = 0.442 to 1.838, p = 0.774) models. No evidence of publication bias was detected during the analysis.The present meta-analysis suggests that the TIMP2 -418 G>C polymorphism may not be involved in predisposing risk factor for cancer in overall population. However, future larger studies with group of populations are needed to analyze the possible correlation.http://europepmc.org/articles/PMC4138026?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Raju K Mandal Naseem Akhter Shafiul Haque Aditya K Panda Rama D Mittal Mohammed A A Alqumber |
spellingShingle |
Raju K Mandal Naseem Akhter Shafiul Haque Aditya K Panda Rama D Mittal Mohammed A A Alqumber No correlation between TIMP2 -418 G>C polymorphism and increased risk of cancer: evidence from a meta-analysis. PLoS ONE |
author_facet |
Raju K Mandal Naseem Akhter Shafiul Haque Aditya K Panda Rama D Mittal Mohammed A A Alqumber |
author_sort |
Raju K Mandal |
title |
No correlation between TIMP2 -418 G>C polymorphism and increased risk of cancer: evidence from a meta-analysis. |
title_short |
No correlation between TIMP2 -418 G>C polymorphism and increased risk of cancer: evidence from a meta-analysis. |
title_full |
No correlation between TIMP2 -418 G>C polymorphism and increased risk of cancer: evidence from a meta-analysis. |
title_fullStr |
No correlation between TIMP2 -418 G>C polymorphism and increased risk of cancer: evidence from a meta-analysis. |
title_full_unstemmed |
No correlation between TIMP2 -418 G>C polymorphism and increased risk of cancer: evidence from a meta-analysis. |
title_sort |
no correlation between timp2 -418 g>c polymorphism and increased risk of cancer: evidence from a meta-analysis. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2014-01-01 |
description |
Tissue inhibitor of metalloproteinase (TIMP2) is involved in the regulation of matrix metalloproteinase 2 (MMP2) and shown to implicate in cancer development and progression. The results from the published studies based on the association between TIMP2 -418 G>C polymorphism and cancer risk are inconsistent. In this meta-analysis, we aimed to evaluate the potential association between TIMP2 -418 G>C polymorphism and cancer risk.We searched PubMed (Medline) and EMBASE web databases to cover all studies based on relationship of TIMP2 -418 G>C polymorphism and risk of cancer until October 2013. The meta-analysis was performed for selected case-control studies and pooled odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated for all genetic models.A total of 2225 cancer cases and 2532 controls were included from ten eligible case-control studies. Results from overall pooled analysis suggested no evidence of significant risk between TIMP2 -418 G>C polymorphism and cancer risk in any of the genetic models, such as, allele (C vs. G: OR = 1.293, 95% CI = 0.882 to 1.894, p = 0.188), homozygous (CC vs. GG: OR = 0.940, 95% CI = 0.434 to 2.039, p = 0.876), heterozygous (GC vs. GG: OR = 1.397, 95% CI = 0.888 to 2.198, p = 0.148), dominant (CC+GC vs. GG: OR = 1.387, 95% CI = 0.880 to 2.187, p = 0.159) and recessive (CC vs. GG+GC: OR = 0.901, 95% CI = 0.442 to 1.838, p = 0.774) models. No evidence of publication bias was detected during the analysis.The present meta-analysis suggests that the TIMP2 -418 G>C polymorphism may not be involved in predisposing risk factor for cancer in overall population. However, future larger studies with group of populations are needed to analyze the possible correlation. |
url |
http://europepmc.org/articles/PMC4138026?pdf=render |
work_keys_str_mv |
AT rajukmandal nocorrelationbetweentimp2418gcpolymorphismandincreasedriskofcancerevidencefromametaanalysis AT naseemakhter nocorrelationbetweentimp2418gcpolymorphismandincreasedriskofcancerevidencefromametaanalysis AT shafiulhaque nocorrelationbetweentimp2418gcpolymorphismandincreasedriskofcancerevidencefromametaanalysis AT adityakpanda nocorrelationbetweentimp2418gcpolymorphismandincreasedriskofcancerevidencefromametaanalysis AT ramadmittal nocorrelationbetweentimp2418gcpolymorphismandincreasedriskofcancerevidencefromametaanalysis AT mohammedaaalqumber nocorrelationbetweentimp2418gcpolymorphismandincreasedriskofcancerevidencefromametaanalysis |
_version_ |
1725978990263402496 |